PSivida shares skyrocket after drug meets trial goals
December 22, 2015 at 11:41 AM EST
Psivida Corp.’s share price shot up to a five-year high in active trade after an eye inflammation treatment met its primary efficacy endpoint in a late-stage clinical trial.
